crovalimab
Trade name: PIASKY
mAbapprovedOrphan Drug FDA
Approved
Jun 20, 2024
Clinical trial activity
10 trials · 2 clinical orgs · 2 marketing orgs
Phase 1
2
Phase 2
9
Phase 3
6
Phase 4
0
Earliest trial started Nov 14, 2016 (NCT03157635)
Timeline
Indications
Approved for
Mechanism of action
- Complement C5INHIBITOR
Complement C5 inhibitor
Approval history
- approvedJun 20, 2024
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL4594316 ↗
Also known as
- ro7112689
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07172022 | Phase 2 | Mar 16, 2026 | Roche |
| NCT05494619 | Phase 3 | Nov 30, 2022 | Roche |
| NCT05075824 | Phase 2 | Dec 17, 2021 | Roche |
| NCT04912869 | Phase 1 | Dec 15, 2021 | Roche |
| NCT04958265 | Phase 3 | Nov 20, 2021 | Chugai, Roche |
| NCT04861259 | Phase 3 | Oct 22, 2021 | Chugai, Roche |
| NCT04654468 | Phase 3 | Mar 10, 2021 | Roche |
| NCT04432584 | Phase 3 | Sep 1, 2020 | Chugai, Roche |
| NCT04434092 | Phase 3 | Aug 2, 2020 | Chugai, Roche |
| NCT03157635 | Phase 1/Phase 2 (Phase 2) | Nov 14, 2016 | Roche |
Showing 10 of 10 trials
Page 1 / 1